Menu Search
Equities

Revolution Medicines Inc

42Z:DEU

Revolution Medicines Inc

Actions
  • Price (EUR)55.00
  • Today's Change0.50 / 0.92%
  • Shares traded725.00
  • 1 Year change+177.78%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Revolution Medicines Inc's revenues fell -67.27% from 35.38m to 11.58m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 248.71m to a larger loss of 436.37m.
Gross margin--
Net profit margin-76,423.31%
Operating margin-88,409.30%
Return on assets-41.28%
Return on equity-47.18%
Return on investment-44.46%
More ▼

Cash flow in USDView more

In 2023, Revolution Medicines Inc increased its cash reserves by 328.55%, or 536.03m. Cash Flow from Financing totalled 1.23bn or 10,614.85% of revenues. In addition the company used 350.57m for operations while cash used for investing totalled 342.60m.
Cash flow per share-3.51
Price/Cash flow per share--
Book value per share9.34
Tangible book value per share8.91
More ▼

Balance sheet in USDView more

Revolution Medicines Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio14.24
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.